VentiRx Pharmaceuticals, Inc. Appoints James Kyle Bryan, M.D. as Chief Medical Officer
4/23/2013 7:38:54 AM
More...
|
VentiRx Pharmaceuticals, Inc. Initiates Randomized, Placebo-Controlled, Phase 2 Trial of VTX-2337 in Patients With Recurrent or Persistent Ovarian Cancer
10/22/2012 9:49:19 AM
More...
|
Celgene Corporation (CELG) Puts $35 Million Into VentiRx Pharmaceuticals, Inc., Gets Option to Buy Cancer Drugmaker
10/3/2012 6:45:23 AM
More...
|
VentiRx Pharmaceuticals, Inc. Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
1/23/2012 10:22:46 AM
More...
|
VentiRx Pharmaceuticals, Inc. Concentrates on Cancer Development to Conserve Cash
9/14/2011 8:34:23 AM
More...
|
VentiRx Pharmaceuticals, Inc. Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
10/7/2010 7:30:54 AM
More...
|
VentiRx Pharmaceuticals, Inc.' Novel TLR8 Agonist, VTX-2337, Successfully Completes Phase 1 Clinical Trial in Oncology
10/4/2010 7:44:00 AM
More...
|
VentiRx Pharmaceuticals, Inc. Raises $25 Million in Series A Extension Financing
1/12/2010 7:07:30 AM
More...
|
VentiRx Pharmaceuticals, Inc. Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
4/16/2009 9:56:28 AM
More...
|
VentiRx Pharmaceuticals, Inc. Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
12/4/2008 9:08:52 AM
More...
|
|